Velagliflozin

Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

Product Specifications

CAS Number

[946525-65-1]

UNSPSC

12352005

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Velagliflozin.html

Concentration

10mM

Purity

99.92

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@H](C2=CC(CC3=CC=C(C4CC4)C=C3)=C(C#N)C=C2)O[C@H](CO)[C@@H](O)[C@@H]1O

Molecular Formula

C23H25NO5

Molecular Weight

395.45

References & Citations

[1]Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41 (2) :266-273.|[2]Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13 (9) :e0203655.